October 19, 2021 10:35 AM EDT
R&D

No­vo CEO Lars Fruer­gaard Jør­gensen on R&D risk, the deal strat­e­gy and tar­gets for gen­der di­ver­si­ty

John Carroll

Editor & Founder



I kicked off our Eu­ro­pean R&D sum­mit last week with a con­ver­sa­tion in­volv­ing No­vo …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Rev­o­lu­tion Med­i­ci­nes' KRAS drug shows po­ten­tial in ear­ly cut of lung can­cer da­ta

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

Ex­clu­sive: Can AI re­place an­i­mal test­ing? A new biotech launch­es to find out

France stops Val­neva's chikun­gun­ya vac­cine roll­out in over 65s af­ter safe­ty is­sue

Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times